I-Tech AB (ITECH) AI Stock Analysis

Top Page

I-Tech AB

(Nasdaq OMX AB:ITECH)

Select Model

Rating:72Outperform

Price Target:SEK 63.00▲(6.24% Upside)

Action:reiterated

Date:10/17/26

Strong financial performance, anchored by a debt-free balance sheet and robust cash generation, is the primary driver. Positive earnings call momentum from growth and margin stability adds support, while fair valuation provides further lift; short-term technical weakness tempers the score.

Positive Factors

High profitability and debt-free balance sheetStrong profitability combined with essentially no leverage gives I-Tech financial resilience and flexibility. The debt-free balance sheet can support investment in products and markets while improving returns on shareholder capital, helping preserve earnings quality through normal business cycles.

Negative Factors

EU regulatory re-registration riskA non-renewal would restrict the use and sale of Selektope-containing paint in the EU, creating a durable regulatory obstacle in an important market. Although management estimates roughly 5% of the addressable market would be affected, compliance costs and transition requirements could still weigh on execution.

I-Tech AB (ITECH) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 711.47M
Dividend Yield: 2.11%
Average Volume (3M): 29.72K
Price to Earnings (P/E): 14.0
Beta (1Y): -0.05
Revenue Growth: 6.19%
EPS Growth: 23.00%
Country: Sweden
Employees: 11
Sector: General
Sector Strength: 55
Industry: Chemicals - Specialty

I-Tech AB Business Overview & Revenue Model

Company Description

I-Tech AB, a biotechnology firm established in Mölndal, Sweden, in 2000, focuses on creating and commercializing products to prevent biofouling. Their flagship innovation is Selektope, a unique bio-repellent ingredient engineered for marine coatings....

I-Tech AB Earnings Call Summary

Earnings Call Date:Oct 15, 2026(Q3-2026)|% Change Since:-18.09%|Next Earnings Date:Feb 03, 2027

Earnings Call SentimentPositive

The call was predominantly positive, with strong Q3 growth, higher profitability, a 60% gross margin, rising cash, favorable shipping-market indicators, and progress in product and market expansion. The main challenges were the uncertain EU re-registration of Selektope, elevated raw material prices, customer-driven revenue volatility, regulatory costs, and the early commercialization stage of the aquaculture technologies.

Positive Updates

Continued Organic Growth

Q3 currency-adjusted sales growth was 18% year over year, continuing I-Tech's growth journey of nearly 30% year on year since its 2018 IPO.

Negative Updates

Q3 Sales Below the Previous Record Quarter

Q3 sales were lower than the previous record quarter, Q2, although management described the quarter as strong overall. The sequential variation was attributed mainly to the timing of large customer orders.

Company Guidance

Management said its target is to keep gross margin at a higher level, with “±2 percentage points” reasonable around the reported 60%; it also targets “more than double-digit growth,” expects staff costs of approximately SEK 5.5 million as a quarterly run rate, and forecasts “a continuously prudent increase of our cost expenditure.” Internal product developments are expected “within, you could say, the coming one to two years,” the biological derived additive “within the coming years,” potentially “two to three years,” while Titanium Technology is “too soon to say”; for the EOGRT study, the company hopes to have “a starting time and a CRO in place within this year,” and a possible EU non-renewal would likely come into force “within this year” with a 180-day grace period.

I-Tech AB Financial Statement Overview

Summary

Strong balance sheet with zero debt, 26.7% ROE, and solid cash conversion at 95% of net income; income statement shows healthy 25.6% net margin and improving EBIT, though gross margin compression and modest revenue growth are watchpoints.

Income Statement

74Positive

Balance Sheet

94Very Positive

Cash Flow

81Very Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	198.83M	168.12M	179.45M	120.86M	83.63M	52.90M
Gross Profit	52.44M	47.43M	95.22M	63.54M	45.13M	27.48M
EBITDA	69.86M	52.58M	57.44M	30.34M	21.19M	1.60M
Net Income	50.85M	33.19M	39.01M	20.20M	10.62M	-2.65M
Balance Sheet
Total Assets	241.10M	193.73M	173.11M	152.44M	125.41M	115.12M
Cash, Cash Equivalents and Short-Term Investments	177.22M	148.16M	100.16M	83.26M	52.75M	35.01M
Total Debt	0	0	7.79M	0	2.25M	4.29M
Total Liabilities	36.55M	19.35M	15.73M	16.20M	9.37M	10.19M
Stockholders Equity	204.55M	174.39M	157.39M	136.24M	116.03M	104.94M
Cash Flow
Free Cash Flow	55.78M	64.51M	35.04M	32.76M	20.06M	-2.43M
Operating Cash Flow	58.66M	64.60M	35.17M	35.14M	20.13M	-1.70M
Investing Cash Flow	-2.88M	-409.00K	-408.00K	-2.38M	-822.00K	-928.00K
Financing Cash Flow	-14.30M	-16.20M	-17.86M	-2.25M	-1.56M	-3.35M

I-Tech AB Technical Analysis

Technical Analysis SentimentNegative

Last Price59.30

Price Trends

50DMA69.26Negative

100DMA68.68Negative

200DMA60.79Negative

Market Momentum

MACD-3.45Positive

RSI37.43Neutral

STOCH49.07Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ITECH, the sentiment is Negative. The current price of 59.30 is below the 20-day moving average (MA) of 63.91, below the 50-day MA of 69.26, and below the 200-day MA of 60.79, indicating a bearish trend. The MACD of -3.45 indicates Positive momentum. The RSI at 37.43 is Neutral, neither overbought nor oversold. The STOCH value of 49.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ITECH.

I-Tech AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

SE:ITECH against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:ITECH	72Outperform	SEK 711.47M	13.98	―	2.11%	6.19%	23.00%
SE:PCAT	65Neutral	SEK 14.87M	4.56	―	―	-17.14%	88.76%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
SE:ORGC	45Neutral	SEK 83.91M	-1.52	-176.65%	―	-21.95%	-28.77%
SE:ENZY	44Neutral	SEK 551.01M	-12.24	―	―	-2.36%	23.44%
SE:POLYG	44Neutral	SEK 85.47M	-19.61	-1.52%	―	-18.26%	35.77%
SE:CLBIO	39Underperform	SEK 371.09M	-28.83	―	―	54.37%	52.22%

* General Sector Average

Performance Comparison

SE:ITECH and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:ITECH	I-Tech AB	59.30	-11.90	-16.71%
SE:POLYG	Polygiene AB	2.34	-7.06	-75.11%
SE:ORGC	OrganoClick AB	0.46	-1.42	-75.64%
SE:ENZY	Enzymatica AB	2.27	0.32	16.41%
SE:CLBIO	Corline Biomedical AB	14.20	-5.75	-28.82%
SE:PCAT	Photocat A/S	2.48	-2.32	-48.33%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 17, 2026

I-Tech AB AI Stock Analysis